We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Disclosures
- Food allergy
- Anaphylaxis
- The top 9 FAs In the US
- Rising burden of food allergy
- Rates of food-induced anaphylaxis are increasing
- Impact of food allergy
- Impact of food allergy - summary
- Oral Immunotherapy (OIT)
- First food allergy therapy available
- IMPACT Study
- Remission rates are higher in younger patients
- POISED phase 2 study
- Threshold sensitivity decreases in most patients
- POISED: regular dosing with peanut is best
- Oral immunotherapy (OIT): benefits and limitations
- Multi-food OIT is safe but slow
- If we target the drivers can we improve the disease?
- Anti-IgE antibody
- Omalizumab facilitates OIT build-up speed
- MAP-X: phase 2 multifood allergen trial with Xolair
- MAPX: phase 2 study at Stanford
- MTAX: omalizumab-facilitated multi-food OIT
- Multi-food OIT induced desensitization
- MIMIX Study
- Participants with high OIT dosing have a slower TTM
- Transition to real food equivalents post-MIMIX
- Omalizumab meta-analysis
- Omalizumab improves multi-allergen OIT
- Omalizumab improves patient Quality of Life (QoL)
- Anti-IgE agents: what we know so far
- Phase 3 multi-OIT with omalizumab
- Multi-OIT with real food equivalents (1)
- Multi-OIT with real food equivalents (2)
- Multi-OIT with real food equivalents (3)
- Omalizumab to accelerate a symptom-driven multi-food OIT
- Ongoing clinical trials with omalizumab
- Comparing ligelizumab and omalizumab
- Ongoing phase 3 clinical trial with ligelizumab
- Atopic march and development of food allergy
- Anti-interleukin 4Rα antibody
- Dupilumab decreases sIgE in patients with AD
- Food allergy studies involving dupilumab
- MAGIC study: phase 2 milk OIT with dupilumab
- COMBINE Study: phase 2 multi-OIT
- COMBINE Study: phase 2 multi-OIT (goal)
- Anti-alarmins targeting IL-33, TSLP, IL-25
- Anti-IL-33 improves threshold sensitivity to peanut
- More to come….
- Patient management of food allergy
- Unanswered questions about therapy for food allergies
- Are biologics a life-long management scenario for food allergy?
- Biologics in management of FA
- Patient selection factors for consideration
- A shared decision-making tree
- Conclusions
- Thank you
Topics Covered
- Food allergy
- Rates of food-induced anaphylaxis are increasing
- Oral Immunotherapy (OIT)
- IMPACT Study
- POISED phase 2 study
- Anti-IgE antibody
- Omalizumab facilitates OIT build-up speed
- MAP-X: phase 2 multifood allergen trial with Xolair
- MIMIX Study
- Omalizumab meta-analysis
- Comparing ligelizumab and omalizumab
- Patient management of food allergy
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Sindher, S.B. (2024, May 30). Biologics as a treatment strategy in food allergy [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved August 23, 2024, from https://doi.org/10.69645/WZIZ3864.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Sindher reports grants from NIH, Regeneron, DBV Technologies, Aimmune, Novartis, CoFAR, and FARE. She is an Advisory member at Genentech.
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
Hello. My name is
Sayantani Sindher.
I'm a Clinical
Associate Professor at
Stanford University and
I am the Director of
the Clinical Translational
Research Unit at the
Sean N. Parker Center for
Allergy and Asthma Research.
Today, I will be discussing
biologics as a treatment
strategy for food allergy.
0:20
I have to disclose
some grant support I
have received from
the NIH, Regeneron,
DBV technologies,
Aimmune, Novartis,
CoFR, and FARE for
the conduct of food
allergy-related clinical trials.
I have also served as an
advisory committee member
for Genentech and
DBV technologies.
0:43
Food allergy is when
your immune system
mounts an inappropriate
response to food antigens.
This process is initiated
when allergenic proteins are
presented by antigen-presenting
cells to naïve T cells
which induce a Th2 response
to the allergens leading
to the production of
allergen-specific
immunoglobulin E or IgE
which becomes displayed
on the surface of mast
cells and basophils.
In subsequent
exposures, the allergen
interacts with the
IgE on the surface of
mast cells and
basophils which causes
degranulation and initiates
the allergic symptoms
that we are familiar with.
1:28
The most severe and concerning
consequence of these reactions
is the potential for
anaphylaxis which can lead
to life-threatening
if not rapidly
treated with
epinephrine followed
by the examination by a
medical professional.
Anaphylaxis includes the
involvement of one's CNS system,
cutaneous system,
cardiovascular,
respiratory as well as
gastrointestinal
systems among others.